Bank of America’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-5,000
Closed -$776K 8230
2024
Q3
$776K Buy
5,000
+700
+16% +$105K ﹤0.01% 5221
2024
Q2
$589K Sell
4,300
-14,700
-77% -$2.01M ﹤0.01% 5248
2024
Q1
$2.53M Buy
+19,000
New +$2.47M ﹤0.01% 4264
2019
Q1
Sell
-5,400
Closed -$450K 7158
2018
Q4
$450K Buy
+5,400
New +$506K ﹤0.01% 4999
2014
Q4
Sell
-71,100
Closed -$4.31M 7721
2014
Q3
$4.31M Buy
71,100
+23,000
+48% +$1.42M ﹤0.01% 2706
2014
Q2
$2.82M Buy
+48,100
New +$2.82M ﹤0.01% 3072
2013
Q3
Sell
-125,000
Closed -$7.58M 7896
2013
Q2
$7.58M Buy
+125,000
New +$7.45M ﹤0.01% 1948

Other funds holding DGX

Bank of America's DGX Position: Q1 2026 in Review

Bank of America increased its Quest Diagnostics (DGX) stake by 8% in Q1 2026, buying an estimated $25.3M and bringing the position to 1,752,902 shares worth $344M. The position accounts for 0.03% of the portfolio, ranked #518.

Bank of America first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $559M in Q4 2021. 1,066 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Bank of America held 1,752,902 shares of Quest Diagnostics worth $344M as of Q1 2026.
  • Bank of America bought 129,964 Quest Diagnostics shares in Q1 2026, an estimated $25.3M.
  • Quest Diagnostics made up 0.03% of Bank of America's portfolio in Q1 2026, its #518 holding.
  • Bank of America first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Quest Diagnostics position peaked at $559M in Q4 2021.
  • 1,066 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.